A guide to neurotoxic animal models of Parkinson's disease

Cold Spring Harbor Perspectives in Medicine

Volumn 1, Issue 1, 2011, Pages

  Tieu, Kim ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTOXIN; OXIDOPAMINE; PARAQUAT; ROTENONE;

ANIMAL; CHEMICALLY INDUCED DISORDER; CORPUS STRIATUM; DISEASE MODEL; HAPLORHINI; INTOXICATION; LEWY BODY; MOUSE; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HAPLORHINI; LEWY BODIES; MICE; MPTP POISONING; NEUROTOXINS; OXIDOPAMINE; PARAQUAT; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; ROTENONE; SUBSTANTIA NIGRA;

EID: 84884907135     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009316     Document Type: Article

References (181)

1. Abe K, Saitoh T, Horiguchi Y, Utsunomiya I, Taguchi K. 2005. Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease. Biol Pharm Bull 28: 1355-1362.
2. Agid Y, Javoy F, Glowinski J, Bouvet D, Sotelo C. 1973. Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. Brain Res 58: 291-301.
3. Albers DS, Sonsalla PK. 1995. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275: 1104-1114.
4. Ali SF, Newport GD, Holson RR, Slikker W Jr., Bowyer JF. 1994. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res 658: 33-38.
5. Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S, GreeneJG. 2007. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol 207: 4-12.
6. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. 1993. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18: 1175-1177.
7. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romaska I, Bojarski A, VetulaniJ. 2004. Protective effect of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7: 155-163.
8. Axt KJ, Mamounas LA, Molliver ME. 1994. Structural features of amphetamine neurotoxicity in the brain. In Amphetamine and its analogs: Psychopharmacology, toxicology, and abuse (ed. Cho AK, Segal DS), pp. 315-367. Academic, New York.
9. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, LeverenzJB, Roncaroli F, Buttini M, Hladik CL, et al. 2008. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 116: 277-288.
10. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, GreenamyreJT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
11. Bezard E. 2011. Parkinson's disease: Animal models-primates Park. Cold Spring Harb Perspect Med doi: 10: 1101/cshperspect. a009308.
12. Bezard E, Przedborski S. 2011. A tale on animal models of Parkinson's disease. Mov Disord 26: 993-1002.
13. Bezard E, Imbert C, Gross CE. 1998. Experimental models of Parkinson's disease: From the static to the dynamic. Rev Neurosci 9: 71-90.
14. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaughtKS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, et al. 2002. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci 99: 2344-2349.
15. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172.
16. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK. 2004. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134.
17. Branchi I, D'Andrea I, Armida M, Cassano T, Pezzola A, Potenza RL, MorgeseMG, Popoli P, Alleva E. 2008. Nonmotor symptoms in Parkinson's disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 86: 2050-2061.
18. Brooks SP, Dunnett SB. 2009. Tests to assess motor phenotype in mice: A user's guide. Nat Rev Neurosci 10: 519-529.
19. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. 1999. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823: 1-10.
20. Cannon JR, Greenamyre JT. 2010. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res 184: 17-33.
21. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. 2009. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34: 279-290.
22. Carlsson A. 1959. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11: 490-493.
23. Carlsson M, Carlsson A. 1989. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65-71.
24. Carlsson A, Lindqvist M, Magnusson T. 1957. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200.
25. Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, Dexter DT. 2010. Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson's disease. Parkinsons Dis pii: 190450.
26. Chaudhuri KR, Yates L, Martinez-Martin P. 2005. The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential. Curr Neurol Neurosci Rep 5: 275-283.
27. Christine CW, Langston JW, Turner RS, Starr PA. 2009. The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism. J Neurosurg 110: 234-238.
28. Cicchetti F, Lapointe N, Roberge-Tremblay A, Saint-Pierre M, Jimenez L, FickeBW, Gross RE. 2005. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol Dis 20: 360-371.
29. Clark DG, McElligott TF, Hurst EW. 1966. The toxicity of paraquat. Br J Ind Med 23: 126-132.
30. Clausing P, Bowyer JF. 1999. Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of d-amphetamine. Ann NY Acad Sci 890: 495-504.
31. Cocheme HM, Murphy MP. 2008. Complex I is the major site of mitochondrial superoxide production by paraquat. J Biol Chem 283: 1786-1798.
32. Cohen G, Werner P. 1994. Free radicals, oxidative stress, and neurodegeneration. In Neurodegenerative diseases (ed. Calne DB), pp. 139-161. W. B. Saunders, Philadelphia.
33. Conway KA, Harper JD, Lansbury PT Jr. 2000. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39: 2552-2563.
34. Corasaniti MT, Defilippo R, Rodino P, Nappi G, Nistico G. 1991. Evidence that paraquat is able to cross the blood-brain barrier to a different extent in rats of various age. Funct Neurol 6: 385-391.
35. Corrodi H, Hanson LC. 1966. Central effects of an inhibitor of tyrosine hydroxylation. Psychopharmacologia 10: 116-125.
36. Cubells JF, Rayport S, Rajendran G, Sulzer D. 1994. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14: 2260-2271.
37. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, et al. 2009. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci 106: 8043-8048.
38. Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J. 1974. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 99: 529-540.
39. Dahlstrom A, Fuxe K. 1964. Localization of monoamines in the lower brain stem. Experientia 20: 398-399.
40. Dauer W, Przedborski S. 2003. Parkinson's disease: Mechanisms and models. Neuron 39: 889-909.
41. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. 1979. Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res 1: 249-254.
42. Dawson TM, Ko HS, Dawson VL. 2010. Genetic animal models of Parkinson's disease. Neuron 66: 646-661.
43. Day BJ, Patel M, Calavetta L, Chang LY, Stamler JS. 1999. A mechanism of paraquat toxicity involving inclusions in MPTP-treated monkeys. Ann Neurol 20: 449-455.
44. DeCuypere M, Lu Y, Miller DD, LeDoux MS. 2008. Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. J Neurochem 107: 1398-1413.
45. Drolet RE, Cannon JR, Montero L, Greenamyre JT. 2009. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 36: 96-102.
46. Dunham NW, Miya TS. 1957. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc (Baltim)46: 208-209.
47. Faull RL, Laverty R. 1969. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp Neurol 23: 332-340.
48. Fernagut PO, Diguet E, Labattu B, Tison F. 2002. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 113: 123-130.
49. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, Chesselet MF. 2007. Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of alpha-synuclein over-expression. Synapse 61: 991-1001.
50. Ferrante RJ, Schulz JB, Kowall NW, Beal MF. 1997. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 753: 157-162.
51. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. 2004a. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24: 9434-9440.
52. Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, ChesseletMF. 2004b. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187: 418-429.
53. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, BuscetiCL, Pontarelli F, Battaglia G, et al. 2005. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci 102: 3413-3418.
54. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. 1986. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20: 449-455.
55. Forno LS, DeLanney LE, Irwin I, Langston JW. 1993. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: Neuropathologic considerations. Adv Neurol 60: 600-608.
56. Fox SH, Brotchie JM. 2010. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog Brain Res 184: 133-157.
57. Fredriksson A, Archer T. 1994. MPTP-induced behavioural and biochemical deficits: A parametric analysis. J Neural Transm Park Dis Dement Sect 7: 123-132.
58. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. 1998. Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 18: 4861-4869.
59. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. 1999. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19: 2424-2431.
60. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. 2002. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem 81: 1285-1297.
61. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276: 2380-2386.
62. Gibb JW, Kogan FJ. 1979. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch Pharmacol 310: 185-187.
63. Giovanni A, Sieber B-A, Heikkila RE, Sonsalla PK. 1994. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 270: 1000-1007.
64. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643.
65. Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, Miller GW. 2008. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J Neurochem 106: 2205-2217.
66. Hefti F, Melamed E, Wurtman RJ. 1980. Partial lesions of the dopaminergic nigrostriatal system in rat brain: Biochemical characterization. Brain Res 195: 123-137.
67. Heikkila RE, Nicklas WJ, Vays I, Duvoisin RC. 1985. Dopaminergic toxicity of rotenone and the MPTP ion after their stereotaxic administration to rats: Implication for the mechanism of MPTP toxicity. Neurosci Lett 62: 389-394.
68. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. 2000. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7: 429-447.
69. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. 1990. Parkinson's disease: A case-control study of occupational and environmental risk factors. Am J Ind Med 17: 349-355.
70. Hirsch EC, Hunot S. 2009. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 8: 382-397.
71. Hoglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC. 2003. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84: 491-502.
72. Hokfelt T, Martensson R, Bjorklund A, Kleinau S, Goldstein M. 1984. Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain. In Handbook of chemical neuroanatomy. Classical transmitters in the CNS, Part I (ed. Bjorklund A, Hokfelt T), pp. 277-379. Elsevier, Amsterdam.
73. Hornykiewicz O, Kish SJ. 1987. Biochemical pathophysiology of Parkinson's disease. In Parkinson's disease (ed. Yahr M, Bergmann KJ), pp. 19-34. Raven Press, New York.
74. Iancu R, Mohapel P, Brundin P, Paul G. 2005. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 162: 1-10.
75. Ilijic E, Guzman JN, Surmeier DJ. 2011. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis doi: 101016/jnbd201104007.
76. Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P. 2005. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22: 317-330.
77. Jain S. 2011. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord 17: 77-83.
78. Jeon BS, Jackson-Lewis V, Burke RE. 1995. 6-hydroxydopamine lesion of the rat substantia nigra: Time course and morphology of cell death. Neurodegeneration 4: 131-137.
79. Jiang H, Jackson-Lewis V, Muthane U, Dollison A, Ferreira M, Espinosa A, Parsons B, Przedborski S. 1993. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 613: 347-351.
80. Joel D, Weiner I. 2000. The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96: 451-474.
81. Jonsson G. 1980. Chemical neurotoxins as denervation tools in neurobiology. Annu Rev Neurosci 3: 169-187.
82. Jonsson G. 1983. Chemical lesioning techniques: Monoamine neurotoxins. InHandbook of chemical neuroanatomy Vol 1: Methods in chemical neuroanatomy(ed. Björklund A, Hökfelt T), pp. 463-507. Elsevier, Amsterdam.
83. Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, et al. 2007. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 165: 364-374.
84. Kikuchi K, Nagatsu Y, Makino Y, Mashino T, Ohta S, Hirobe M. 1991. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1, 2, 3, 4-Tetrahydroisoquinoline and 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline. Drug Metab Dispos 19: 257-262.
85. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, BjorklundA. 2002. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci 99: 4708-4713.
86. Kita T, Matsunari Y, Saraya T, Shimada K, O'Hara K, Kubo K, Wagner GC, Nakashima T. 2000. Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci 18: 521-530.
87. Krasnova IN, Cadet JL. 2009. Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407.
88. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. 1987. Parkinson's disease and megacolon: Concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37: 1253-1255.
89. Langston JW. 2006. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59: 591-596.
90. Langston JW, Ballard P, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
91. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 46: 598-605.
92. Lapointe N, St-Hilaire M, Martinoli MG, Blanchet J, Gould P, Rouillard C, Cicchetti F. 2004. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18: 717-719.
93. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. 1997. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 48: 1583-1588.
94. Lorenc-Koci E, Antkiewicz-Michaluk L, Wardas J, Zapala M, Wieronska J. 2004. Effect of 1, 2, 3, 4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12, 935 to dopamine transporter in the rat nigrostriatal, dopaminergic system. Brain Res 1009: 67-81.
95. Luthman J, Fredriksson A, Sundstrom E, Jonsson G, Archer T. 1989. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: Motor behavior and monoamine alterations at adult stage. Behav Brain Res 33: 267-277.
96. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. 2010. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem 285: 13621-13629.
97. Malmfors T, Sachs C. 1968. Degeneration of adrenergic nerves produced by 6-hydroxydopamine. Eur J Pharmacol 3: 89-92.
98. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. 2002. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. J Biol Chem 277: 1641-1644.
99. Martin I, Dawson VL, Dawson TM. 2010. The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res 183: 21-41.
100. McCormack AL, Di Monte DA. 2003. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem 85: 82-86.
101. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. 2002. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10: 119-127.
102. Meredith GE, Sonsalla PK, Chesselet MF. 2008. Animal models of Parkinson's disease progression. Acta Neuropathol 115: 385-398.
103. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. 2002. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 277: 19213-19219.
104. Mizuno Y, Sone N, Saitoh T. 1987. Effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 48: 1787-1793.
105. Musshoff F, Lachenmeier DW, Schmidt P, Dettmeyer R, Madea B. 2005. Systematic regional study of dopamine, norsalsolinol, and (R/S)-salsolinol levels in human brain areas of alcoholics. Alcohol Clin Exp Res 29: 46-52.
106. Nagatsu T. 1997. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 29: 99-111.
107. Nagatsu T, Yoshida M. 1988. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 87: 178-182.
108. Naoi M, Maruyama W, Akao Y, Yi H. 2002. Dopamine-derived endogenous N-methyl-(R)-salsolinol: Its role in Parkinson's disease. Neurotoxicol Teratol 24: 579-591.
109. +, a metabolite of the neurotoxin MPTP. Life Sci 36: 2503-2508.
110. Nishimura F, Yoshikawa M, Kanda S, Nonaka M, Yokota H, Shiroi A, Nakase H, Hirabayashi H, Ouji Y, Birumachi J, et al. 2003. Potential use of embryonic stem cells for the treatment of mouse parkinsonian models: Improved behavior by transplantation of in vitro differentiated dopaminergic neurons from embryonic stem cells. Stem Cells 21: 171-180.
111. Niwa T, Takeda N, Tatematsu A, Matsuura S, Yoshida M, Nagatsu T. 1988. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. J Chromatogr 452: 85-91.
112. Niwa T, Yoshizumi H, Tatematsu A, Matsuura S, Nagatsu T. 1989. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J Chromatogr 493: 347-352.
113. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. 1985. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50: 435-441.
114. Okuda K, Kotake Y, Ohta S. 2006. Parkinsonism-preventing activity of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo. Biol Pharm Bull 29: 1401-1403.
115. Ossowska K, Wardas J, Smialowska M, Kuter K, Lenda T, Wieronska JM, Zieba B, Nowak P, Dabrowska J, Bortel A, et al. 2005. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: An animal model of preclinical stages of Parkinson's disease? Eur J Neurosci 22: 1294-1304.
116. Parker WD Jr., Boyson SJ, Parks JK. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723.
117. Perry TL, Jones K, Hansen S. 1988. Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice. Neurosci Lett 85: 101-104.
118. Porter CC, Totaro JA, Stone CA. 1963. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J Pharmacol Exp Ther 140: 308-316.
119. Porter CC, Totaro JA, Burcin A. 1965. The relationship between radioactivity and norepinephrine concentrations in the brains and hearts of mice following administration of labeled methyldopa or 6-hydroxydopamine. J Pharmacol Exp Ther 150: 17-22.
120. Przedborski S. 2007. Neuroinflammation and Parkinson's disease. Handb Clin Neurol 83: 535-551.
121. Przedborski S, Tieu K. 2006. Toxic animal models. In Neurodegenerative diseases (ed. Beal MF, et al.), pp. 196-221. Cambridge University Press, Cambridge.
122. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM. 1995. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67: 631-647.
123. Przedborski S, Jackson-Lewis V, Naini A, Jakowec M, Petzinger G, Miller R, Akram M. 2001. The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 76: 1265-1274.
124. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
125. Rappold PM, Tieu K. 2010. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 7: 413-423.
126. Ricaurte GA, Sabol KE, Seiden LS. 1994. Functional consequences of neurotoxic amphetamine exposure. In Amphetamine and its analogs: Psychopharmacology, toxicology, and abuse (ed. Cho AK, Segal DS), pp. 297-313. Academic, New York.
127. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. 2005. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 88: 193-201.
128. Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, Bronstein J. 2009. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 117: 964-969.
129. Rojas JC, Simola N, Kermath BA, Kane JR, Schallert T, Gonzalez-Lima F. 2009. Striatal neuroprotection with methylene blue. Neuroscience 163: 877-889.
130. Rommelspacher H, Susilo R. 1985. Tetrahydroisoquinolines and beta-carbolines: Putative natural substances in plants and mammals. Prog Drug Res 29: 415-459.
131. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. 2006. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12: 1259-1268.
132. Rozas G, López-Martín E, Guerra MJ, Labandeira-García JL. 1998. The overall rod performance test in the MPTP-treated-mouse model of parkinsonism. J Neurosci Meth 83: 165-175.
133. Saint-Pierre M, Tremblay ME, Sik A, Gross RE, Cicchetti F. 2006. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats. J Neurochem 98: 760-772.
134. Saner A, Thoenen H. 1971. Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 7: 147-154.
135. Sarre S, Yuan H, Jonkers N, Van HA, Ebinger G, Michotte Y. 2004. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 90: 29-39.
136. Sauer H, Oertel WH. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415.
137. Scally MC, Ulus IH, Wurtman RJ, Pettibone DJ. 1978. Regional distribution of neurotransmitter-synthesizing enzymes and substance P within the rat corpus striatum. Brain Res 143: 556-560.
138. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269.
139. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW. 1985. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233: 539-544.
140. Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M. 1997. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: Structure-activity relationships. Biochem Pharmacol 54: 1361-1369.
141. Sedelis M, Schwarting RK, Huston JP. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125: 109-125.
142. Segal DS, Kuczenski R. 1994. Behavioral pharmacology of amphetamine. InAmphetamine and its analogs: Psychopharmacology, toxicology, and abuse (ed. Cho AK, Segal DS), pp. 115-150. Academic, New York.
143. Senoh S, Witkop B. 1959. Nonenzymatic conversions of dopamine to norepinephrine and trihydroxyphenethylamine. J Am Chem Soc 81: 6222-6231.
144. Senoh S, Creveling CR, Udenfriend S, Witkop B. 1959. Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J Am Chem Soc 81: 6236-6240.
145. Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, Suno M, Ogawa K, Hayase N, Kimura K, et al. 2001. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 906: 135-142.
146. Smith P, Heath D. 1976. Paraquat. CRC Crit Rev Toxicol 4: 411-445.
147. Smith Y, Kieval JZ. 2000. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 23: S28-S33.
148. Snyder SH, D'Amato RJ. 1985. Predicting Parkinson's disease. Nature 317: 198-199.
149. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED. 1996. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 738: 172-175.
150. Spectors S, Sjoerdsma A, Udenfriend S. 1965. Blockade of endogenous norepinephrine synthesis by alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther 147: 86-95.
151. Sulzer D, Maidment NT, Rayport S. 1993. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60: 527-535.
152. Sulzer D, Chen T-K, Lau YY, Kristensen H, Rayport S, Ewing A. 1995. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15: 4102-4108.
153. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da CC, Takahashi RN. 2008. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156: 830-840.
154. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, et al. 2011. Rotenone, paraquat and Parkinson's disease. Environ Health Perspect 119: 866-872.
155. Tassin JP, Cheramy A, Blanc G, Thierry AM, Glowinski J. 1976. Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum. I. Mictoestimation of [3H] dopamine uptake and dopamine content in microdiscs. Brain Res 107: 291-301.
156. Taylor TN, Greene JG, Miller GW. 2010. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 211: 1-10.
157. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. 2000a. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease? Brain Res 873: 225-234.
158. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. 2000b. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for Parkinson's disease. J Neurosci 20: 9207-9214.
159. Thiruchelvam M, McCormack A, Richfield EK, Baggs RB, Tank AW, Di MonteDA, Cory-Slechta DA. 2003. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18: 589-600.
160. Thomas DM, Francescutti-Verbeem DM, Kuhn DM. 2008. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 105: 605-616.
161. Thumen A, Behnecke A, Qadri F, Bauml E, Thumen A, Behnecke CA, Qadri F, Bauml E, Moser A. 2002. N-Methyl-norsalsolinol, a putative dopaminergic neurotoxin, passes through the blood-brain barrier in vivo. Neuroreport 13: 25-28.
162. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, Naini A, Vila M, Jackson-Lewis V, Ramasamy R, et al. 2003. D-β-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson's disease. J Clin Invest 112: 892-901.
163. Tranzer JP, Thoenen H. 1968. An electron microscopic study of selective, acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine. Experientia 24: 155-156.
164. Tranzer JP, Thoenen H. 1973. Selective destruction of adrenergic nerve terminals by chemical analogues of 6-hydroxydopamine. Experientia 29: 314-315.
165. Trulson ME, Cannon MS, Faegg TS, Raese JD. 1985. Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: Tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res Bull 15: 569-577.
166. Ungerstedt U. 1968. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107-110.
167. Ungerstedt U, Arbuthnott G. 1970. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.
168. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. 2000. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74: 721-729.
169. West MJ. 1993. New stereological methods for counting neurons. Neurobiol Aging 14: 275-285.
170. West MJ, Slomianka L, Gundersen HJ. 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
171. West MJ, Ostergaard K, Andreassen OA, Finsen B. 1996. Estimation of the number of somatostatin neurons in the striatum: An in situ hybridization study using the optical fractionator method. J Comp Neurol 370: 11-22.
172. Widmann R, Sperk G. 1986. Topographical distribution of amines and major amine metabolites in the rat striatum. Brain Res 367: 244-249.
173. Yoshida M, Niwa T, Nagatsu T. 1990. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes. Neurosci Lett 119: 109-113.
174. Yoshida M, Ogawa M, Suzuki K, Nagatsu T. 1993. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. Adv Neurol 60: 207-211.
175. Yuan J, Callahan BT, McCann UD, Ricaurte GA. 2001. Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem 77: 1338-1347.
176. Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA. 2002. Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem 80: 960-969.
177. Yuan J, Darvas M, Sotak B, Hatzidimitriou G, McCann UD, Palmiter RD, RicaurteGA. 2010. Dopamine is not essential for the development of methamphetamine-induced neurotoxicity. J Neurochem 114: 1135-1142.
178. Zaborszky L, Vadasz C. 2001. The midbrain dopaminergic system: Anatomy and genetic variation in dopamine neuron number of inbred mouse strains. Behav Genet 31: 47-59.
179. Zaczek R, Culp S, De Souza EB. 1991a. Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther 257: 830-835.
180. Zaczek R, Culp S, Goldberg H, Mccann DJ, De Souza EB. 1991b. Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J Pharmacol Exp Ther 257: 820-829.
181. Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, DiCarlo CD, Seaman RL, Chesselet MF. 2004. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 478: 418-426.